A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

6.6K views

⸱

DOI:

10.3791/61037

⸱

May 1st, 2020

 ,  ,  ,  ,  ,  ,  , 

In This Article

Summary

This protocol describes the use of macromolecular crowding to create an in vitro human hypertrophic scar tissue model that resembles in vivo conditions. When cultivated in a crowded macromolecular environment, human skin fibroblasts exhibit phenotypes, biochemistry, physiology, and functional characteristics resembling scar tissue.

Abstract

It has been shown that in vivo tissues are highly crowded by proteins, nucleic acids, ribonucleoproteins, polysaccharides, etc. The following protocol applies a macromolecular crowding (MMC) technique to mimic this physiological crowding through the addition of neutral polymers (crowders) to cell cultures in vitro. Previous studies using Ficoll or dextran as crowders demonstrate that the expression of collagen I and fibronectin in WI38 and WS-1 cell lines are significantly enhanced using the MMC technique. However, this technique has not been validated in primary hypertrophic scar-derived human skin fibroblasts (hHSFs). As hypertrophic scarring arises from the excessive deposition of collagen, this protocol aims to construct a collagen-rich in vitro hypertrophic scar model by applying the MMC technique with hHSFs. This optimized MMC model has been shown to possess more similarities with in vivo scar tissue compared to traditional 2-dimensional (2-D) cell culture systems. In addition, it is cost-effective, time-efficient, and ethically desirable compared to animal models. Therefore, the optimized model reported here offers an advanced “in vivo-like” model for hypertrophic scar-related studies.

Introduction

Scar tissue represents the endpoint of tissue repair. However, in many individuals, especially those suffering from burns or trauma1, scarring can be excessive and impose undesirable effects on the morphology and functioning of healed skin. Although the exact mechanisms of pathological (hypertrophic scars and keloids) scar formation are not fully understood, excessive deposition of collagen during wound healing has been demonstrated to be an essential contribution2.

It is well-established that transforming growth factor beta 1 (TGF-β1) and alpha smooth muscle actin (αSMA) play key ro....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Cell culture

  1. Maintain hHSFs and normal dermal fibroblasts derived from non-pathological tissue (hNSFs) in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS) and 1% v/v penicillin/streptomycin solution (P/S) at 37°C in an incubator with 5% CO2/95% air.
  2. Purchase Ficoll 70, Ficoll 400, and ascorbic acid from the appropriate companies.

2. Construction of MMC hypertrophic scar model

  1. Seed the hHSFs or hNSFs (50,000/well) into a 24 well plate containing 1 mL of media in each well.
  2. Place in a 37°C incubator at 5% CO2 and leave ....

Access restricted. Please log in or start a trial to view this content.

Results

Triplicate samples were performed in each experiment, and each experiment was repeated 3x using cells from three individual patients. Data are expressed as percentages of the control group. One-way ANOVA and Tukey's post-hoc test were applied to analyze statistical differences (*p ˂ 0.05).

MMC using Ficoll at 9% FVO (fractional volume occupancy) enhances the total amount of collagen and collagen I deposition in hHSF13. As illustrated in Fig.......

Access restricted. Please log in or start a trial to view this content.

Discussion

This protocol aims to optimize and authenticate an improved :scar-in-a-jar” in vitro model for human cutaneous scar tissue. Previous studies have reported the application of MMC technique to human lung fibroblasts12, human bone marrow mesenchymal stem cells23, and human dermal fibroblasts23 using dextran12, Ficoll12, and PVP23 as crowders. In the study reported here, the pr.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no conflicts of interest.

Acknowledgements

This work was supported by funding from Singapore's Agency for Science, Technology and Research “SPF 2013/004: Skin Biology Basic Research” and the “Wound Care Innovation for the Tropics” IAF-PP/2017 (HBMS) H17/01/a0/009. The authors gratefully acknowledge advice and assistance from Dr. Paula Benny and Dr. Michael Raghunath.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
0.2 μm filterSartorius16534
2-MercaptoethanolSigma-AldrichM6250
4’,6-diamidino-2-phenylindole (DAPI)Thermo Fisher ScientificP36962
Alexa Fluor 680Thermo Fisher ScientificA-21076
Alexa Fluor 800Thermo Fisher ScientificA-11371
alpha smooth muscle actin (αSMA) primary antibodyAbcamab5694
Applied Biosystems 7500 Fast Real-Time PCR System (thermal cycler )Thermo Fisher Scientific4351106
Ascorbic acidWako#013-12061
Bovine serum albuminSigma-Aldrich#A2153
Bradford protein assayBio-Rad500-0006
Collagen I primary antibody (for immunostaining)Abcam6308
Collagen I primary antibody (for western blot)Abcamab21286
Collagen III primary antibodyAbcamab7778
Collagen IV primary antibodyAbcamab6586
Direct Red 80Sigma-Aldrich2610108
Dulbecco's Modified Eagle's Medium (DMEM)Life Technologies11996-065
Fetal calf serum (FCS)Life Technologies6000-044
Ficoll 400GE HealthCare#17-0300-10
Ficoll 70GE HealthCare#17-0310-10
GAPDH primary antibodySigma-AldrichG8795
Goat Anti-Rabbit secondary antibodyAbcamab97050
Human hypertrophic scar/normal fibroblasts (hHSF/hNSF)Cell Research Corporation106, 107, 108
iScript cDNA Synthesis KitBio-Rad#1708890
MMP-1 primary antibodyAbcamab38929
MMP-13 primary antibodyAbcamab39012
MMP-2 primary antibodyAbcamab37150
MMP-9 primary antibodyAbcamab38898
NanoDrop Microvolume SpectrophotometersThermo Fisher ScientificN/A
Nitrocellulose membraneBio-Rad10484060
NuPAGE 4-12% Bis-Tris Protein GelsThermo Fisher ScientificNP0321BOX
Odyssey blocking bufferLI-COR Biosciences927–40000
Odyssey Fc Imaging SystemLI-COR BiosciencesN/A
Olympus IX-81 HCS microscope (for immunostaining)OlympusN/A
Penicillin/streptomycin solution (P/S)Life Technologies15140-122
PrimePCR AssaysBio-RadCustomized primers pre-coated in 96-well plates based on requirement
Protease inhibitor cocktail (PIC)Sigma-Aldrich11697498001
PVP 360Sigma#PVP360
PVP 40Sigma#PVP40
RIPA bufferMerckR0278
RNeasy Plus Mini KitQIAGEN#74134
Sodium vanadateSigma-Aldrich450022
Sodium vanadateSigma-Aldrich450243
SpectraMax M5 Multi-Mode microplate readerMolecular DevicesN/A
SsoAdvanced universal SYBR green supermixBio-Rad#172-5270
Tween 20Sigma-AldrichP9416

References

  1. vander Veer, W. M., et al. Potential cellular and molecular causes of hypertrophic scar formation. Burns. 35 (1), 15-29 (2009).
  2. Linge, C., et al. Hypertrophic Scar Cells Fail....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Collagen DepositionFicoll 70Ficoll 400Sirius Red StainingWestern BlotRT-PCR AnalysisHuman Skin FibroblastsExtracellular Matrix